RESEARCH HIGHLIGHTS Nature Reviews Cardiology 11, 618 (2014); published online 16 September 2014; doi:10.1038/nrcardio.2014.139
HEART FAILURE
LCZ696—a PARADIGM shift in treatment for heart failure experienced serious angio-oedema in clinical trials. Therefore, LCZ696 includes an angiotensin-receptor blocker instead of an ACE inhibitor to minimize the risk of this adverse effect. In the double-blind PARADIGM‑HF trial, investigators randomly allocated 8,442 patients with NYHA class II–IV HF and an ejection fraction ≤40% to receive either LCZ696 (200 mg twice daily) or enalapril (10 mg twice daily), in addition to recommended therapy. The trial was stopped early (median follow-up 27 months) because of an overwhelming benefit with LCZ696 therapy. The composite primary end point (cardiovascular mortality and hospitalization for HF) occurred in 21.8% of patients receiving LCZ696 compared with 26.5% of those receiving enalapril (HR 0.80, 95% CI 0.73–0.87, P
HEART FAILURE
LCZ696—a PARADIGM shift in treatment for heart failure experienced serious angio-oedema in clinical trials. Therefore, LCZ696 includes an angiotensin-receptor blocker instead of an ACE inhibitor to minimize the risk of this adverse effect. In the double-blind PARADIGM‑HF trial, investigators randomly allocated 8,442 patients with NYHA class II–IV HF and an ejection fraction ≤40% to receive either LCZ696 (200 mg twice daily) or enalapril (10 mg twice daily), in addition to recommended therapy. The trial was stopped early (median follow-up 27 months) because of an overwhelming benefit with LCZ696 therapy. The composite primary end point (cardiovascular mortality and hospitalization for HF) occurred in 21.8% of patients receiving LCZ696 compared with 26.5% of those receiving enalapril (HR 0.80, 95% CI 0.73–0.87, P
